A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
Latest Information Update: 13 May 2022
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Proof of concept; Therapeutic Use
- 19 May 2020 Status changed from active, no longer recruiting to completed.
- 06 Sep 2019 Planned End Date changed from 1 Dec 2020 to 1 Mar 2020.
- 06 Sep 2019 Status changed from recruiting to active, no longer recruiting.